These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 15653654)

  • 1. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
    Okarvi SM
    Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry in Peptide radionuclide receptor therapy: a review.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotargeted gene therapy.
    Buchsbaum DJ; Chaudhuri TR; Zinn KR
    J Nucl Med; 2005 Jan; 46 Suppl 1():179S-86S. PubMed ID: 15653667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor expression in GEP-NET.
    Reubi JC
    Virchows Arch; 2007 Aug; 451 Suppl 1():S47-50. PubMed ID: 17684767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs.
    Mariani G; Erba PA; Signore A
    J Nucl Med; 2006 Dec; 47(12):1904-7. PubMed ID: 17138731
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting.
    Reubi C; Gugger M; Waser B
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):855-62. PubMed ID: 12111125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and perspectives in peptide receptor radiation therapy.
    Ansquer C; Kraeber-Bodéré F; Chatal JF
    Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy targeted to cancers through tumoral hormone receptors.
    Schally AV; Nagy A
    Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals.
    Khan IU; Beck-Sickinger AG
    Anticancer Agents Med Chem; 2008 Feb; 8(2):186-99. PubMed ID: 18288921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based radiopharmaceuticals for targeted tumor therapy.
    Dong C; Liu Z; Wang F
    Curr Med Chem; 2014; 21(1):139-52. PubMed ID: 23992337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications.
    Bodei L; Paganelli G; Mariani G
    J Nucl Med; 2006 Mar; 47(3):375-7. PubMed ID: 16513604
    [No Abstract]   [Full Text] [Related]  

  • 20. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.
    Reubi JC
    Neuroendocrinology; 2004; 80 Suppl 1():51-6. PubMed ID: 15477718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.